You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

CLINICAL TRIALS PROFILE FOR SGN-CD19A

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for SGN-CD19A

Subscribe to access the full database, or Get Started Free
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01786096 ↗	A Safety Study of SGN-CD19A for Leukemia and Lymphoma	Completed	Seagen Inc.	Phase 1	This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
NCT01786096 ↗	A Safety Study of SGN-CD19A for Leukemia and Lymphoma	Completed	Seattle Genetics, Inc.	Phase 1	This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
NCT01786135 ↗	A Safety Study of SGN-CD19A for B-Cell Lymphoma	Completed	Seagen Inc.	Phase 1	This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
NCT01786135 ↗	A Safety Study of SGN-CD19A for B-Cell Lymphoma	Completed	Seattle Genetics, Inc.	Phase 1	This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in patients with relapsed or refractory B-lineage non-Hodgkin lymphoma (B-NHL)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for SGN-CD19A

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Follicular Lymphoma, Grade 3b	2
Lymphoma, Large B-Cell, Diffuse	2
Precursor B-cell Lymphoblastic Leukemia-Lymphoma	2
Burkitt Lymphoma	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Lymphoma	4
Lymphoma, Large B-Cell, Diffuse	3
Lymphoma, Follicular	3
Lymphoma, B-Cell	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for SGN-CD19A

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	54
Puerto Rico	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
New York	4
California	4
Texas	3
Georgia	3
Florida	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for SGN-CD19A

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Terminated	2
Completed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SGN-CD19A

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Seattle Genetics, Inc.	4
Seagen Inc.	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	8
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.